SemaThera Inc

SemaThera Inc

Biotechnology Research Ca 6 employees
Employees
6
Contacts
3
Emails
3
Phones
1

SemaThera Inc Overview

Headquarters
Ca
Website
semathera.com
Industry
Biotechnology Research
Employees
6
Founded
2016
Funding
2.6M
Company Email
Available in AeroLeads
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About SemaThera Inc

SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.

SemaThera Inc Contact Details

People in AeroLeads
4
With contact data
3
Email contacts
3
75.0% coverage
Phone contacts
1
25.0% coverage

SemaThera Inc Org Chart

Sample employees and titles
Name Title Contact
Garth C.
View
Véronique Bougie Executive with a Passion for Innovation
Email Phone
Mike (Przemyslaw) Sapieha Endowed Chair of Ophthalmology Research
Email
Elizabeth Douville, Phd, Icd.d Life Sciences Executive
Email

Employees by Management Level

Individual contributor 5 profiles

Department Contact Coverage

Department Contacts Email Phone
General 2 2 1

SemaThera Inc Tech Stack

Data / AI 2 profiles

Compare Similar Companies to SemaThera Inc